This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

MannKind Afrezza Partnership News Coming Within Weeks

By: Adam Feuerstein | 07/25/14 - 11:30 AM EDT

Stocks in this article: MNKD

Exactly four weeks have passed since MannKind (MNKD) secured FDA approval for its inhaled insulin device Afrezza. But with no announcement from MannKind executives about a partnership necessary to sell Afrezza, the company's stock is sliding down hill.

MNKD Chart
MNKD data by YCharts


Mannkind executives may be forced to say something about the state of Afrezza partnership discussions very soon, even if no deal is in place. That's because MannKind must report second-quarter financials before the end of the second week in August. Historically, MannKind reports second-quarter financials in early August. Last year's reporting date was Aug. 9; the year before, it was Aug. 7. MannKind has not announced a date for the upcoming second quarter financials yet, but it must happen by Aug. 15, per SEC reporting rules. 

If MannKind is close to signing an Afrezza partnership, the company is almost certainly pushing very hard to get that deal closed before it must report second-quarter financials. The alternative is ugly. Holding a conference call in early or middle August with nothing concrete to say about an Afrezza deal would be damaging to MannKind. Investors are growing tired of optimistic partnership talk that goes nowhere

At one point earlier this summer, MannKind (sort of) promised an Afrezza partnership 6-8 weeks after FDA approval. Soon after, MannKind tried to walk back that expectation. Afrezza was approved on June 27, so 6-8 weeks out is Aug. 8 through Aug. 22, which overlaps with the requirement to report second-quarter results. 

The waiting is hard, but one way or another, we should hear something more definitive from MannKind about an Afrezza deal (or the lack of one) within weeks, at the latest.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.

Markets

DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs